Apertura Gene Therapy is a biotechnology company that treats debilitating diseases with limited options.
Apertura Gene Therapy has raised $67.0M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
Apertura Gene Therapy's investors include Deerfield.
Apertura Gene Therapy is headquartered in Newyork, United Kingdom.
Apertura Gene Therapy is a biotechnology company that treats debilitating diseases with limited options.
Apertura Gene Therapy is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apertura Gene Therapy — Funding & Investors." VCBacked, April 26, 2022, https://www.vcbacked.co/company/apertura-gene-therapy. Accessed September 30, 2026.
VCBacked. (2022). Apertura Gene Therapy — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/apertura-gene-therapy
{{cite web |title=Apertura Gene Therapy — Funding & Investors |url=https://www.vcbacked.co/company/apertura-gene-therapy |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated